SCHEDULE 13G/A: Alger Associates Discloses 5.7% Stake in Absci Corporation

Alger Associates, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 5.7% in Absci Corporation's common stock as of December 31, 2024.

Summary

• Alger Associates, Inc., a New York-based holding company, has reported beneficial ownership of 6,505,423 shares of Absci Corporation's common stock.
• This ownership represents 5.7% of Absci Corporation's outstanding common stock.
• The filing indicates that Alger Associates, Inc. holds sole voting power and sole dispositive power over all 6,505,423 shares.
• The securities are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC (FAM), a registered investment adviser and a 100% owned subsidiary of Alger Group Holdings, LLC, which is in turn a 100% owned subsidiary of Alger Associates, Inc.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of Absci Corporation.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment about the company's performance or prospects. It is a neutral regulatory filing.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant passive investment by Alger Associates, Inc. in Absci Corporation, a biotechnology company. Such filings are standard disclosures for institutional investors acquiring more than 5% of a company's stock, providing transparency to the market about major ownership stakes. It suggests that Alger Associates views Absci as a viable investment within its managed portfolios.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
• Company Management: Awareness of a large, passive institutional holder, though the filing explicitly states the stake is not for control purposes.

Key Dates

Keywords

Absci Corporation, Alger Associates Inc., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Biotechnology, Pharmaceuticals